# Medpace account plan

> Medpace: Cincinnati full-service clinical CRO for Phase I-IV trials, $2,530.2 million FY2025 revenue and about 6,600 employees in 46 countries.

## At a glance

Medpace Holdings, Inc. is a Cincinnati-based, full-service clinical contract research organization running Phase I-IV trials for biotechnology, pharmaceutical and medical device companies, and positions itself as a partner of choice for small and mid-sized biopharmaceutical companies. Its integrated offering spans medical leadership, trial management on its proprietary ClinTrak system, monitoring, regulatory affairs, biometrics, central and bioanalytical laboratories and Phase I clinics. FY2025 revenue was $2,530.2 million (+20.0%) and net income $451.1 million. It had about 6,600 employees across 46 countries at 30 September 2026, carries no debt and is listed on Nasdaq; founder August J. Troendle controls about 19.0% of the shares.

## Business units

- **Oncology** ($747.6 million FY2025 revenue (about 29.5%)): The largest therapeutic area, growing every year shown; Q3 2026 revenue was $229.9 million, overtaking Metabolic for the quarter as the mix shifts back toward traditional oncology.
- **Metabolic** ($745.0 million FY2025 revenue (about 29.4%)): Fastest-growing area in FY2025, heavily weighted to obesity and diabetes, and the main driver of higher pass-through costs. Management expected its share of revenue to fall in 2026; nine-month 2026 revenue was $665.9 million.
- **Central Nervous System** ($254.8 million FY2025 revenue (about 10.1%)): One of the three areas behind FY2025 growth; Q3 2026 revenue rose to $83.6 million from $65.6 million.
- **Cardiology** ($239.4 million FY2025 revenue (about 9.5%)): Supported by the cardiovascular core laboratory; broadly stable, at $61.4 million in Q3 2026.
- **Antiviral and Anti-infective (AVAI)** ($134.9 million FY2025 revenue (about 5.3%)): A declining area, supported by central laboratory molecular and viral testing; $31.8 million in Q3 2026.
- **Other therapeutic areas** ($408.5 million FY2025 revenue (about 16.1%)): All other indications, slightly down in FY2025 and $100.0 million in Q3 2026.

## Strategic priorities

- **Grow Phase I-IV market share**: Expand mainly organically through the full-service model and therapeutic depth, with only "potentially highly selective bolt-on acquisitions and investments".
- **Win rate and awards**: Process changes made late in 2025 to raise the win rate; net new business awards reached $873.4 million in Q3 2026 (+10.6%) and trailing 12-month awards grew 23.9%.
- **Small and mid-sized biotech focus**: Large pharma "is not a focus"; purely functional (FSP) outsourcing is declined in favour of full-service projects.
- **Hiring and retention**: Hiring growth in the mid to high single digits in 2026, with margin gains from retention and utilization rather than restructuring; headcount rose from about 6,200 to about 6,600 in nine months.
- **Capital return**: A new buyback authorization of up to $1.0 billion until 31 December 2028, after $912.9 million of repurchases in 2025.

## Latest results

In Q3 2026 revenue rose 8.5% to $716.0 million and GAAP net income to $137.5 million ($4.84 per diluted share), with EBITDA up 16.0% to $172.1 million (24.0% margin). Nine-month revenue was $2,129.9 million (+16.9%). Backlog reached $3,167.2 million (+5.6%), with $1,980.0-2,000.0 million expected to convert over the next twelve months. 2026 guidance is revenue of $2.835-2.855 billion (+12.0% to 12.8%), GAAP net income of $514.0-524.0 million and EBITDA of $638.0-652.0 million; 2027 guidance comes in February.

## Investments and deals

- **Cincinnati campus expansion**: A significant expansion of the Cincinnati campus will add about $20 million of operating costs in 2027; capital spending rose to 2.39% of revenue over nine months of 2026.
- **Share repurchases**: 2,961,924 shares bought for $912.9 million in 2025 and 705,616 shares for $294.7 million in 2026; a new authorization of up to $1.0 billion was approved effective 20 October 2026.
- **AI adoption**: First AI uses target efficiency across the organisation and data analytics for feasibility and site selection; management expects the investment to at least equal the benefits in 2026.

## Challenges and risks

- **Contract cancellations**: Q4 2025 backlog cancellations were the highest in over a year, and Q3 2026 cancellations were toward the higher end of the expected range, now driven mainly by product failure and safety signals.
- **Customer and therapeutic concentration**: Top 5 and top 10 customers were roughly 31% and 39% of trailing 12-month revenue; several trials in one therapeutic class can be cancelled together.
- **AI disruption**: The CEO calls AI, on the surface, a net negative for a service company paid to provide staff over a period of years; the 10-K also flags a competitive risk from under-investing in AI tools.
- **Client acquisitions by large pharma**: When large pharma buys a biotech client, Medpace generally keeps the work but loses the client long term.

## What leadership says

> "The business environment remains strong" — August J. Troendle, Chairman and Chief Executive Officer, Q3 2026 earnings call, 22 October 2026

> "Cancellations were elevated again in Q4. Backlog cancellations in absolute and percent terms were the highest they've been in over a year." — August J. Troendle, Chairman and Chief Executive Officer, Q4 and full year 2025 earnings call, 10 February 2026

> "some of the crazy approaches taken by some in the past few years have died out. I think we are kind of back to a normalized environment" — August J. Troendle, Chairman and Chief Executive Officer, Q3 2026 earnings call, 22 October 2026, on pricing


## Where a supplier can help

- **Site selection and feasibility analytics**: Tied to AI adoption, whose first uses include data analytics for feasibility and site selection: data and analytics providers for trial planning.
- **Training and talent tools**: Tied to the hiring and retention priority: learning, recruiting and retention tools for a company that hires ahead and trains its own staff.
- **Campus build-out and laboratory equipment**: Tied to the Cincinnati campus expansion: facilities, fit-out and laboratory suppliers.
- **Patient recruitment**: Tied to the challenge of cancellations and the 10-K risk on investigator and patient recruitment: recruitment and retention services that keep studies on track.
- **Biotech pipeline intelligence**: Tied to the small and mid-sized biotech focus and the win-rate priority: market intelligence that helps business development find funded sponsors.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Medpace Holdings, Inc. Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000006/medp-20251231.htm)

Annual report · 2026-02-10

- Medpace is a Cincinnati-based, full-service clinical contract research organization (CRO) running Phase I-IV trials for the biotechnology, pharmaceutical and medical device industries, positioned as a partner of choice for small and mid-sized biopharmaceutical companies.
- FY2025 revenue was $2,530.2 million (+20.0% vs $2,109.1 million), income from operations $534.9 million and net income $451.1 million (FY2024: $404.4 million).
- Reimbursed out-of-pocket expenses (pass-throughs) rose 34.6% to $1,037.5 million; growth was driven by Metabolic, Oncology and Central Nervous System work.
- Net new business awards were $2,646.8 million (FY2024: $2,230.0 million); backlog reached $3,027.2 million (+4.3%), of which about $1,890.0-1,910.0 million is expected to convert to revenue in 2026.
- One reportable segment; revenue by therapeutic area: Oncology $747.6 million, Metabolic $745.0 million, Other $408.5 million, CNS $254.8 million, Cardiology $239.4 million, AVAI $134.9 million.
- About 6,200 employees across 46 countries; U.S. contracting entities account for about 99% of revenue.
- Top ten customers represent about 35.1% of net revenue, no customer above 10%.
- Capital return: 2,961,924 shares repurchased for $912.9 million in 2025; no debt; cash $497.0 million; $821.7 million of authorization left at year-end.
- Founder and CEO August J. Troendle controls about 19.0% of the shares; risks flagged include contract cancellations, backlog conversion, customer/therapeutic concentration and AI.

### [Medpace Holdings, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000036/medp-20260930.htm)

Interim report · 2026-10-22

- Q3 2026 revenue was $716.0 million (+8.5% vs $659.9 million); nine-month revenue $2,129.9 million (+16.9%).
- Q3 net income was $137.5 million (Q3 2025: $111.1 million); nine-month net income $382.7 million (vs $316.0 million).
- Net new business awards were $873.4 million in Q3 (vs $789.6 million) and $2,287.6 million over nine months (vs $1,910.2 million).
- Backlog was $3,167.2 million at 30 September 2026 (+5.6%); $1,980.0-2,000.0 million is expected to convert to revenue over the next twelve months.
- Growth came mainly from Metabolic, Oncology and CNS; Q3 Oncology revenue was $229.9 million and Metabolic $209.2 million.
- Reimbursed out-of-pocket expenses rose only 3.8% in Q3 (to $287.3 million) after +25.9% over nine months.
- About 6,600 employees across 46 countries; cash $705.3 million, no debt.
- 705,616 shares repurchased for $294.7 million in 2026, none in Q3; on 20 October 2026 the Board replaced the program with a new authorization of up to $1.0 billion.

### [Medpace Holdings, Inc. Reports Third Quarter 2026 Results (press release, 8-K Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1668397/000166839726000034/medp-20261021exx991.htm)

Interim report · 2026-10-21

- Q3 2026 revenue $716.0 million, up 8.5% (8.6% at constant currency), with a backlog conversion rate of 23.8%.
- Net new business awards $873.4 million, up 10.6%; backlog $3,167.2 million, up 5.6%.
- GAAP net income $137.5 million or $4.84 per diluted share (Q3 2025: $111.1 million, $3.86); net income margin 19.2%.
- EBITDA $172.1 million, up 16.0%, a 24.0% margin (22.5% a year earlier).
- Year to date: revenue $2,129.9 million (+16.9%), net income $382.7 million, EBITDA $474.9 million (22.3% margin).
- 2026 guidance: revenue $2.835-2.855 billion (+12.0% to 12.8%), GAAP net income $514.0-524.0 million, EBITDA $638.0-652.0 million, diluted EPS $17.97-18.32.
- New buyback authorization of up to $1.0 billion until 31 December 2028, replacing $527.0 million left on the old program; cash $705.3 million.

### [Medpace Q3 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/10/22/medpace-medp-q3-2026-earnings-call-transcript/)

Executive talk · August J. Troendle, Chairman and Chief Executive Officer · 2026-10-22

- CEO August Troendle: the business environment "remains strong"; net new business awards reached an all-time high and trailing 12-month awards grew 23.9%.
- No 2027 guidance until February, but Troendle sees "no large disconnect" between analyst consensus and Medpace's current modeling of 2027; Q4 awards and cancellations will decide it.
- Cancellations were "toward the higher end" of the expected range, now driven mainly by product failure and safety signals rather than funding.
- Mix is shifting back toward traditional oncology, with "a little bit less metabolic demand", though many metabolic opportunities are pending.
- Win-rate process changes made at the end of 2025 are judged "very successful"; pricing environment is "back to a normalized environment".
- CFO Kevin Brady: 2026 revenue guidance $2.835-2.855 billion, EBITDA $638-652 million; pass-throughs expected around 40-40.5% of revenue.
- A significant Cincinnati campus expansion will add about $20 million of operating costs in 2027.
- Top 5 and top 10 customers are roughly 31% and 39% of trailing 12-month revenue; large pharma work mostly follows acquired biotech clients.

### [Medpace Q4 and full year 2025 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/02/10/medpace-medp-q4-2025-earnings-call-transcript/)

Executive talk · August Troendle, Chief Executive Officer · 2026-02-10

- CEO August Troendle: Q4 2025 backlog cancellations were "the highest they've been in over a year", giving a net book-to-bill of 1.04; he rated the environment "adequate and headed in the right direction".
- Cancellations were widespread and skewed toward metabolic; metabolic, heavily obesity/diabetes, should decrease as a share of revenue in 2026.
- Full-year 2025: revenue $2.53 billion (+20%), EBITDA $557.7 million (+16.1%), net income $451.1 million, net awards $2.65 billion (+18.7%).
- 2026 guidance at the time: revenue $2.755-2.855 billion (+8.9% to 12.8%), EBITDA $605-635 million, EPS $16.68-17.50; pass-throughs 41-42% of revenue.
- Hiring to accelerate to mid-to-high single-digit growth in 2026; margin gains come from retention and utilization, not restructuring.
- On AI, Troendle expects no net productivity gain in 2026 and calls it, on the surface, "a net negative" for staff-based service companies over years; first uses target efficiency and feasibility/site selection.
- Top five and top 10 customers were roughly 25% and 35% of 2025 revenue; large pharma "is not a focus".

## Questions about Medpace

### What does Medpace do?

Medpace is a full-service clinical contract research organization that runs Phase I-IV trials for biotechnology, pharmaceutical and medical device companies, mainly small and mid-sized biopharma.

### What is Medpace's revenue?

FY2025 revenue was $2,530.2 million, up 20.0%. For 2026 Medpace guides to $2.835-2.855 billion.

### How many employees does Medpace have?

About 6,600 employees across 46 countries as of 30 September 2026, up from about 6,200 at the end of 2025.

### Who leads Medpace?

Founder August J. Troendle is Chief Executive Officer, President and Chairman; Kevin M. Brady is Chief Financial Officer.

### Which therapeutic areas matter most to Medpace?

Oncology and Metabolic each brought about 29% of FY2025 revenue, followed by Other areas, CNS, Cardiology and AVAI.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
